Related Experiment Video

Updated: May 19, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

MAP kinase signaling and inhibition in melanoma

R J Sullivan1, K Flaherty

  • 1Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA 02114, USA.

Oncogene
|September 5, 2012
PubMed

Insights

Targeting the MAPK pathway with BRAF and MEK inhibitors offers advances in melanoma treatment. Understanding resistance mechanisms is key to developing more effective, long-lasting targeted therapies for melanoma patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • The mitogen-activated protein kinase (MAPK) pathway is a key driver in malignant melanoma.
  • NRAS and BRAF mutations significantly impact melanoma prognosis and treatment strategies.
  • Targeted therapies inhibiting MAPK pathway components have improved patient outcomes.

Purpose of the Study:

  • To review the role of the MAPK pathway in melanoma.
  • To discuss the efficacy and limitations of current MAPK pathway inhibitors.
  • To explore emerging strategies for overcoming therapeutic resistance in melanoma.

Main Methods:

  • Literature review of studies on MAPK pathway signaling in melanoma.
  • Analysis of clinical trial data for BRAF and MEK inhibitors.
  • Synthesis of current knowledge on melanoma treatment resistance mechanisms.

Main Results:

  • Selective BRAF inhibitors like vemurafenib improve survival in BRAF-mutant melanoma.
  • MEK inhibitors show activity in BRAF-mutant melanomas.
  • Therapeutic benefit duration is often limited by resistance mechanisms.

Conclusions:

  • Targeted therapies have advanced melanoma treatment, particularly for BRAF-mutant cases.
  • Further research into resistance mechanisms is crucial for improving combination regimens and treatment sequences.
  • A deeper understanding of MAPK pathway biology will guide the development of more effective molecularly targeted therapies.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...